Subscription Required

Only paid subscribers* to Specialty Pharmacy News can access this Web portal with three years of back issues, searchable article archives and other valuable resources.

Subscribers to Specialty Pharmacy News receive

  • 12 monthly issues packed with news and strategies on this increasingly vital sector in health business, delivered First Class by U.S. Mail and electronically (optional),
  • E-News Alerts whenever important news breaks, and
  • Access to a subscriber-only Web page with:
    • Searchable archives of past articles,
    • Convenient library with PDFs of back issues,
    • Recent stories of interest and hot topic articles grouped for convenient reading, and
    • Regular postings from Managing Editor Angela Maas.
View a sample and get more information
June 2015

Recent Stories of Interest

From Specialty Pharmacy News - When Gilead Sciences, Inc.’s hepatitis C drug Harvoni (ledipasvir/sofosbuvir) came onto the market last fall, its impressive clinical trial data were almost lost in the uproar over its price — $1,125 per pill per day. The drug is indicated for genotype 1 patients, which is the most common hepatitis C infection in the U.S., and its label allows for treatment regimens of eight, 12 and 24 weeks based on certain patient characteristics. Read more

A class of drugs that traditionally has had only nonspecialty medications available… Read more

Almost seven years after accepting an application for a generic version of… Read more

Interest in the pharmacy sector shows no signs of waning, as yet… Read more

From the Editor

Welcome to your Specialty Pharmacy News subscriber-only Web page

Be sure to visit often, for PDFs of issues, archives of articles and data, and more!

Please e-mail me with your comments on the last issue of Specialty Pharmacy News, story ideas for future issues, or any other suggestions you have that can make the newsletter more useful for you.

June 19, 2015
Generic Copaxone Finally Launches

Court of Appeals invalidates Teva's Copaxone patent; Sandoz launches generic Glatopa at reported 15% discount

June 15, 2015
CVS to Revamp Target's Pharmacies

CVS Health plans to acquire and rebrand Target's in-store pharmacy/clinic locations for $1.9 billion.

June 12, 2015
FDA Expands Promacta Use for Chronic ITP

FDA approves Novartis’ Promacta for use in children at least six years old with chronic immune thrombocytopenia; initial approval was in 2008 for use in adults

Updated Regularly

Featured Hot Topics

Search for your own Hot Topics

It's quick and easy to sign up for FREE access to!

Why do I need to register?